If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Uipath Inc (PATH)
Doubleverify Holdings, Inc. (DV)
Skywater Technology, Inc. (SKYT)
Neuropace Inc (NPCE)
Knowbe4, Inc. (KNBE)
Zymergen Inc. (ZY)
Agiliti, Inc (AGTI)
Latham Group, Inc. (SWIM)
Priced IPO
Biomea Fusion, Inc. (BMEA)
Akoya Biosciences, Inc. (AKYA)
Recursion Pharmaceuticals, Inc. (RXRX)
Karat Packaging Inc. (KRT)
AppLovin (APP)
Esports Technologies (EBET)
Agilon Health, Inc. (AGL)
TuSimple Holdings Inc (TSP)
Coinbase Global, Inc. (COIN)
Alkami Technology, Inc. (ALKT)
Reneo Pharmaceuticals, Inc. (RPHM)
Vectivbio Holding Ag (VECT)
UTime Limited (UTME)
Frontier Group Holdings (ULCC)
Compass, Inc. (COMP)
Smart Share Global Limited (EM)
Karooooo Ltd. (KARO)
Achilles Therapeutics Inc. (ACHL)
Coursera, Inc. (COUR)
Alignment Healthcare, Inc. (ALHC)
More companies

Terns Pharmaceuticals, Inc. (TERN)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Their most advanced program is TERN-101, a liver-distributed, non-bile acid Farnesoid X Receptor agonist that has demonstrated sustained liver FXR activation, as well as a favorable tolerability profile across multiple Phase 1 clinical trials. In their Phase 1 clinical trials, no pruritus, or itching, or increases in LDL cholesterol levels as compared to the control group were observed—unlike in Phase 1 clinical trials of certain other FXR agonists conducted by third parties. They initiated their Phase 2a clinical trial of TERN-101 in NASH patients (the LIFT study) in June 2020 and expect top-line data in the third quarter of 2021. Their second clinical stage program, TERN-201, is a highly selective inhibitor of Vascular Adhesion Protein-1. They intend to start their Phase 1b clinical trial of TERN-201 in NASH patients in the first half of 2021 and expect top-line data in the first half of 2022. Their third program entering the clinic is TERN-501, a Thyroid Hormone Receptor beta, agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-b compared to other THR-b agonists in development. They intend to start their Phase 1 first-in-human clinical trial of TERN-501 in the first half of 2021 and expect top-line data in the second half of 2021.
Senthil Sundaram Mark Vignola
Employees Founded
30 2016


Address: 1065 East Hillsdale Blvd., Suite 100 Foster City, California 94404

Telephone: (650) 525-5535

Web page:

IPO information

First Trade Date 2/5/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 6.25
Shares Revised (MM) 7.5
Expected offer amount (MM) $100
Realized offer amount(MM) $127.5

Financial Data (last reporting year)

Market Cap (MM) $363.52
Revenues (MM) $0
Net Income (Loss) (MM) $-39.9


What do you think will happen with the TERN share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: JP Morgan

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
JP Morgan/ Goldman Sachs/ Cowen

Sector: Healthcare

Tweets about $TERN

Tweets volume:

RT volume:


Google Trends Stats